• Je něco špatně v tomto záznamu ?

Importance of vancomycin loading doses in intermittent infusion regimens

M. Šíma, J. Hartinger, T. Cikánková, O. Slanař,

. 2018 ; 24 (4) : 247-250. [pub] 20171128

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, pozorovací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc18033500

PURPOSE: Delayed achievement of target vancomycin serum concentrations may adversely affect clinical outcomes. The objective of this retrospective study was to explore the real frequency of loading dose use and to evaluate the impact of loading dose for the achievement of vancomycin PK/PD target in adult patients treated with intermittent vancomycin. As a secondary aim we determined optimal vancomycin loading dose based on individual pharmacokinetic calculations. METHODS: Vancomycin pharmacokinetic models were computed using two-compartmental analysis. Based on these models AUC24 were calculated. Unpaired t-test was used to compare AUC24 achieved in patients treated with and without vancomycin loading dose. RESULTS: Vancomycin loading dose was administered only in 17.8% patients. Volume of distribution and clearance median values (interquartile range) for vancomycin in whole study population (n = 45) were 0.69 (0.55-0.87) L/kg and 0.0304 (0.0217-0.0501) L/h/kg, respectively. The AUC24 was significantly higher in patients taking loading dose compared with the group without loading dose: mean (SD) AUC24 was 496 (101) vs. 341 (77) mg h/L. Proportion of patients reaching PK/PD goal was 87.5% and 24.3% with and without loading dose administration, respectively. Considering individual pharmacokinetic parameters optimal vancomycin loading dose was 27.5 mg/kg of body weight. CONCLUSIONS: Loading dose administration plays crucial part in rapid attainment of vancomycin PK/PD target in adult patient treated with intermittent vancomycin, although it is not frequently used in clinical practise. The optimal loading dose of 25-30 mg/kg of body weight should be routinely administered to adult patients treated with intermittent vancomycin.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033500
003      
CZ-PrNML
005      
20240522100346.0
007      
ta
008      
181008s2018 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jiac.2017.11.002 $2 doi
035    __
$a (PubMed)29195829
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Šíma, Martin $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Albertov 4, 128 00 Prague 2, Czech Republic. Electronic address: martin.sima@lf1.cuni.cz.
245    10
$a Importance of vancomycin loading doses in intermittent infusion regimens / $c M. Šíma, J. Hartinger, T. Cikánková, O. Slanař,
520    9_
$a PURPOSE: Delayed achievement of target vancomycin serum concentrations may adversely affect clinical outcomes. The objective of this retrospective study was to explore the real frequency of loading dose use and to evaluate the impact of loading dose for the achievement of vancomycin PK/PD target in adult patients treated with intermittent vancomycin. As a secondary aim we determined optimal vancomycin loading dose based on individual pharmacokinetic calculations. METHODS: Vancomycin pharmacokinetic models were computed using two-compartmental analysis. Based on these models AUC24 were calculated. Unpaired t-test was used to compare AUC24 achieved in patients treated with and without vancomycin loading dose. RESULTS: Vancomycin loading dose was administered only in 17.8% patients. Volume of distribution and clearance median values (interquartile range) for vancomycin in whole study population (n = 45) were 0.69 (0.55-0.87) L/kg and 0.0304 (0.0217-0.0501) L/h/kg, respectively. The AUC24 was significantly higher in patients taking loading dose compared with the group without loading dose: mean (SD) AUC24 was 496 (101) vs. 341 (77) mg h/L. Proportion of patients reaching PK/PD goal was 87.5% and 24.3% with and without loading dose administration, respectively. Considering individual pharmacokinetic parameters optimal vancomycin loading dose was 27.5 mg/kg of body weight. CONCLUSIONS: Loading dose administration plays crucial part in rapid attainment of vancomycin PK/PD target in adult patient treated with intermittent vancomycin, although it is not frequently used in clinical practise. The optimal loading dose of 25-30 mg/kg of body weight should be routinely administered to adult patients treated with intermittent vancomycin.
650    _2
$a senioři $7 D000368
650    _2
$a antibakteriální látky $x aplikace a dávkování $x krev $x farmakokinetika $x farmakologie $7 D000900
650    _2
$a plocha pod křivkou $7 D019540
650    _2
$a počítačová simulace $7 D003198
650    _2
$a kreatinin $x krev $7 D003404
650    _2
$a monitorování léčiv $x metody $7 D016903
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a infuzní pumpy $7 D007260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a vankomycin $x aplikace a dávkování $x krev $x farmakokinetika $x farmakologie $7 D014640
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Hartinger, Jan $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Albertov 4, 128 00 Prague 2, Czech Republic. Electronic address: jan.hartinger@vfn.cz. $7 xx0224709
700    1_
$a Cikánková, Tereza, $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Albertov 4, 128 00 Prague 2, Czech Republic. Electronic address: terez.dan@seznam.cz. $d 1986- $7 xx0268197
700    1_
$a Slanař, Ondřej $u Department of Pharmacology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Albertov 4, 128 00 Prague 2, Czech Republic. Electronic address: ondrej.slanar@lf1.cuni.cz.
773    0_
$w MED00005760 $t Journal of infection and chemotherapy $x 1437-7780 $g Roč. 24, č. 4 (2018), s. 247-250
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29195829 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20240522100342 $b ABA008
999    __
$a ok $b bmc $g 1339479 $s 1030494
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 24 $c 4 $d 247-250 $e 20171128 $i 1437-7780 $m Journal of infection and chemotherapy $n J Infect Chemother $x MED00005760
LZP    __
$a Pubmed-20181008

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...